Acusphere’s Imagify Hit Hard With FDA Panel Rejection
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee cites myriad trial design, safety and efficacy concerns in overwhelmingly negative vote; Acusphere suspends Nasdaq trading.